Biopharmaceutical News and Research

RSS

Imaxio closes EUR 2.9 million funding round

Imaxio, a biopharmaceutical company specialized in the areas of vaccines and genomics, announces today that it has finalized a funding round in which it raised EUR 2.9 million from its principal shareholder, Pradeyrol Developpement.

17 Apr 2012

ThromboGenics resubmits ocriplasmin BLA with FDA to treat symptomatic VMA

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.

17 Apr 2012

Vanda acquires license from Lilly to develop and commercialize NK-1R antagonist

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, announced today that it has acquired an exclusive world-wide license from Eli Lilly and Company (Lilly) to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.

17 Apr 2012

Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference

Novasep, a provider of purification-based manufacturing solutions for lifescience molecules, has announced that Cerenis Therapeutics has been invited by BioProcess International to present its major project CER – 001 ApoA1 - HDL mimetic drug candidate, and describe how Novasep played a critical role in the project by successfully achieving the transfer and scale up of Apo-A1 production.

16 Apr 2012

FDA clears Cerecor’s FP01 IND for treatment of cough

Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that its Investigational New Drug (IND) Application for FP01 for the treatment of cough has cleared the 30 day deliberation period by the U.S. Food and Drug Administration.

12 Apr 2012

Genstar Capital enters definitive agreement to acquire ERT

eResearchTechnology, Inc. (ERT), a global technology-driven provider of health outcomes research services to biopharmaceutical sponsors and contract research organizations (CROs), today announced that it has entered into a definitive agreement to be acquired by affiliates of Genstar Capital LLC, a leading middle market private equity firm for $8.00 per share in cash in a transaction valued at approximately $400 million.

10 Apr 2012

Provectus announces data from PV-10 Phase 2 study on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.

10 Apr 2012

Canon, MEDIAN to demonstrate LMS clinical application portfolio at ITEM

MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, announced today it will demonstrate its Lesion Management Solutions -LMS- clinical application portfolio together with Canon at ITEM, April 13-15, 2012 in Yokohama, Japan.

10 Apr 2012

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury.

9 Apr 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting.

5 Apr 2012

Dohmen announces acquisition of BioSoteria

CEO Cynthia (Dohmen) LaConte announced today that the Dohmen Company has acquired BioSoteria, a leading provider of drug safety and risk management services to the biopharmaceutical industry.

4 Apr 2012

Novel tetracyclines with improved potency, efficacy against contemporary P. aeruginosa isolates

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs.

2 Apr 2012

ProteinSimple introduces Sally Western Blot

ProteinSimple today introduced Sally as the next member of the revolutionary Simple Western product family. Sally eliminates a critical bottleneck in large-scale protein research and biopharmaceutical development – manual Western Blot analysis. With Sally, researchers can perform 96 Simple Westerns in a single automated experiment.

From ProteinSimple 2 Apr 2012

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.

2 Apr 2012

Dyax, GE Healthcare partner to develop and commercialize c-Met imaging peptides

GE Healthcare, a unit of GE, and Dyax Corp. today announced a licensing agreement for the development and commercialization of peptides binding to c-Met, which provides upfront, milestone, and royalty payments to Dyax.

2 Apr 2012

Nile Therapeutics to sell 3.6 million shares of common stock

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has entered into a definitive agreement to sell 3.6 million shares of its common stock at a price per share of $0.40 for aggregate gross proceeds of $1.44 million.

31 Mar 2012

Top-line results from Shire's SPD476 phase 3 trial on diverticulitis

Shire plc, the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis.

31 Mar 2012

AlphaCore Pharma commences ACP-501 Phase 1 study in coronary arterial disease

AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.

31 Mar 2012

Thermo Fisher introduces new HyPerforma S.U.B. TK system

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific HyPerforma Single-Use Bioreactor TK (S.U.B. TK), an integrated system that combines the company's proven single-use bioreactor technology with a robust controller platform that enhances functionality and greatly reduces setup times before each production run.

From Thermo Fisher Scientific Inc. 30 Mar 2012